Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: CAN-508
  • Price: $550.0/100mg $950.0/250mg $1900.0/1g $2100.0/100mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

140651-18-9

140651-18-9 structure
140651-18-9 structure
  • Name: CAY10574
  • Chemical Name: 4-[(3,5-diamino-1H-pyrazol-4-yl)hydrazinylidene]cyclohexa-2,5-dien-1-one
  • CAS Number: 140651-18-9
  • Molecular Formula: C9H10N6O
  • Molecular Weight: 218.215
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
  • Create Date: 2016-07-16 20:22:47
  • Modify Date: 2024-01-14 20:18:14
  • CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].

Name 4-[(3,5-diamino-1H-pyrazol-4-yl)hydrazinylidene]cyclohexa-2,5-dien-1-one
Synonyms 3tn8
2clx
Cdk9 Inhibitor II
Phenol, 4-[(E)-2-(3,5-diamino-1H-pyrazol-4-yl)diazenyl]-
4-[(E)-(3,5-Diamino-1H-pyrazol-4-yl)diazenyl]phenol
F18
CAN-508
Description CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
Related Catalog
Target

CDK9/cyclinT1:0.35 μM (IC50)

CDK2/cyclinE:20 μM (IC50)

cdk2/cyclin A:69 μM (IC50)

Cdk4/cyclin D1:13.5 μM (IC50)

CDK7/cyclin H:26 μM (IC50)

Cdk1/cyclin B:44 μM (IC50)

In Vitro CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays[1]. CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC50s ranging from 34.99 to 91.09 μM[2]. CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells[2]. Apoptosis Analysis[1] Cell Line: SKGT4, OE33 and FLO-1 cells Concentration: 40 μM Incubation Time: 72 hours Result: Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.
In Vivo CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts[1]. Animal Model: 4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)[1] Dosage: 60 mg/kg Administration: I.p.; daily for 10 days Result: Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.
References

[1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.

Density 1.7±0.1 g/cm3
Boiling Point 638.3±55.0 °C at 760 mmHg
Molecular Formula C9H10N6O
Molecular Weight 218.215
Flash Point 339.8±31.5 °C
Exact Mass 218.091614
PSA 125.67000
LogP 0.40
Vapour Pressure 0.0±2.0 mmHg at 25°C
Index of Refraction 1.803